Efficacy of Re-purposed Fluvoxamine in COVID-19 Patients: a systematic review

Efficacy of Re-purposed Fluvoxamine in COVID-19 Patients: a systematic review

The methods and end points of the efficacy of re-purposed Fluvoxamine in coronavirus disease 2019 (COVID-19) patients are varied and the results have not been adopted by the United States Food and Drug Administration to date. We did a systematic review of the efficacy of Fluvoxamine according to search results from the PubMed database with the keywords COVID-19, SARS-CoV-2, novel coronavirus 2019, 2019-nCoV, and Fluvoxamine. A total of 39 articles were found. A total of four studies(1-4) were obtained after screening. The data were calculated with the Mantel-Haenszel risk ratios (RR) with 95% CI by the Comprehensive Meta-Analysis (3).